Arvinas (ARVN)

• Market cap: $1.26B
• 1 day: 3.62%
• 5 days: -1.77%
• 1 month: 6.33%
• 3 months: -26.52%
• 6 months: -23.10%
• Year to date: -3.07%
• 1 year: -62.91%
• 5 years: -63.60%
• 10 years: 14.08%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 430

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

11% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 64

0% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 27

0% less funds holding

Funds holding: 205 [Q2] → 204 (-1) [Q3]

0.82% less ownership

Funds ownership: 107.65% [Q2] → 106.84% (-0.82%) [Q3]

8% less capital invested

Capital invested by funds: $1.96B [Q2] → $1.81B (-$154M) [Q3]

19% less call options, than puts

Call options by funds: $5.79M | Put options by funds: $7.15M

29% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 5 (-2) [Q3]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $32 75% upside
• Avg. target: $58 219% upside
• High target: $87 375% upside

7 analyst ratings

• positive: 7 100%
• neutral: 0 0%
• negative: 0 0%

Oppenheimer Matthew Biegler 14% 1-year accuracy 4 / 29 met price target	146% upside $45	Outperform Maintained	12 Feb 2025
BMO Capital Etzer Darout 20% 1-year accuracy 8 / 41 met price target	348% upside $82	Outperform Reiterated	12 Feb 2025
Guggenheim Michael Schmidt 33% 1-year accuracy 9 / 27 met price target	211% upside $57	Buy Reiterated	12 Feb 2025
Stifel Bradley Canino 18% 1-year accuracy 6 / 33 met price target	179% upside $51	Buy Maintained	12 Feb 2025
Barclays Peter Lawson 12% 1-year accuracy 3 / 25 met price target	75% upside $32	Overweight Maintained	3 Feb 2025